Skip Main Links
Prescribing Information
Important Safety Information
For Healthcare
Providers
Sign Me Up

Change is possible
with XYWAV

Ask your doctor about the first and only FDA‑approved
treatment for adults with Idiopathic Hypersomnia (IH)

You could wake up on the bright side. XYWAV is a treatment studied across the multiple symptoms of IH, such as:

Excessive daytime sleepiness

Sleep inertia

Severe grogginess or confusion when waking up regardless of how much sleep you get or how many alarms you set—feeling disoriented, irritable, or even clumsy when waking up and for hours afterwards

Cognitive impairment

Difficulty focusing, trouble thinking clearly, or memory problems due to excessive daytime sleepiness—often described as “brain fog”

Long sleep time

Ability to sleep for many hours of the day—
sometimes for 11 hours or more

Ready to learn how to treat your IH?

You’ve tried different ways to manage your IH.

It may be time to try XYWAV, the only medication approved by the FDA to treat IH.

Why Treat IH?

Managing your IH with stimulants?

Discover XYWAV—unlike stimulants and wake‑promoting agents that are taken during the day, XYWAV is different—it's taken at night.

Why XYWAV?

Understand how multiple symptoms of IH may affect you throughout your day and learn more about how XYWAV may help.

Take the quiz

My life used to be consumed by sleep, but taking XYWAV twice nightly helps me fight daytime sleepiness. I wake up each morning with less sleep inertia and don’t need to nap as much during the day.

Diana, XYWAV IH Ambassador

Real patient compensated for their time. Individual results may vary.

Find a provider who can see if XYWAV may be right for you.

Find a Doctor

Get information and stay supported

From learning more about your IH, to helping start the conversation with your doctor, and exploring XYWAV as a treatment option—take charge of your journey with support every step of the way.

Sign Up For Emails
Up Arrow Icon
Sign Me Up

This site is intended for U.S. residents ages 18 and older.

© 2024 Jazz Pharmaceuticals, Inc. US-XYW-2200433 Rev1124